Interim report Q2 2021

April – June · Revenues amounted to MSEK 747.9 (688.9), corresponding to an increase of +9% for the period. · The organic growth[1] during the second quarter was +8%. The currency impact in the quarter was 0% while the acquisitions of the product portfolios Pevaryl[®] from Johnson & Johnson and Flux[®], Decubal[®], Apobase[®], Lactocare[®] from Teva generated growth of +1%. · EBIT (Operating Profit) amounted to MSEK 31.0 (98.6), corresponding to a decline of 69%. · EBITDA[1] amounted to MSEK 180.7 (226.1) corresponding to a decline of 20%. · The gross margin, defined as